Serum Biomarkers in the MORGAM Populations

风险因素的作用，如升高的血液胆固醇和血压心脏病，以确定未来的心脏病和中风已经知道了三十多年。最近，血液中蛋白质（C反应蛋白）的水平已被证明可以提高预测能力，但需要更好的预测来识别风险增加的患者，预防工作可以集中在这些患者身上。要做到这一点，有必要对大量人群进行随访，看看许多新的蛋白质（生物标志物）是否可以提高我们识别心脏病或中风风险较高的人的能力。我们需要研究人类群体，因为在动物中研究这些新因素的意义是可疑的。MORGAM是一个大型的欧洲研究，包括9个国家的120，000名男性和女性。所有这些人的血清样本都是可用的，我们将使用最新的技术来测量19种生物标志物，其中一些是非常新颖的。在英国样本中获得的结果将在其他欧洲国家分别在男性和女性中进行验证。在这种情况下，我们计划得出一个评分系统，以量化未来发生心脏病发作的可能性，以便采取措施避免它们。该小组设在贝尔法斯特女王大学、芬兰赫尔辛基和德国美因茨。

The role of risk factors, such as raised blood cholesterol and blood pressure to heart disease, to determining future heart disease and stroke has been known for more than thirty years. More recently the level of a protein (C reactive protein)in the blood has been shown to improve prediction but better prediction is needed to identify patients at increased risk, on whom preventive efforts can be concentrated. To do this it is necessary to follow up large groups of people to see if many novel new proteins (biomarkers) can improve our ability to identify persons at higher risk of developing heart disease or stroke. We need to study human populations as the reevance of studing these new factors in animals is dubious. MORGAM is a large European studt which has included 120,000 men and women in 9 countries. A sample of serum is available for all these persons and we will use the latest tecchnology to measure a battery of 19 Biomarkers, some of which are highly novel. The results obtained in the United Kingdom samples will be verified in other European poulations, in men and women separately. In this fashion we plan to derive a scoring system to quantify the cahace of developing a heart attack in the future so that steps can be taken to avert them. The Team is based at the Queen s University of Belfast and in Helsinki, Finland, and in Mainz, Germany.